EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

Accelerated Multi-Target Theta-Burst Stimulation for Obsessive–Depressive–Anxious Symptoms: Real-World Outcomes of the aTTODA Protocol

Álvaro Moleón-Ruiz iD, Lucía Duque-Fernández iD, Clara Regidor, Paloma Álvarez de Toledo iD, Gonzalo Martín-García, Lorena García-Fernández iD, Francisco Javier Narbona-Antunez iD, Luis Gutiérrez-Rojas iD, Roberto Rodriguez-Jimenez iD, Manuela Martín-Bejarano iD

Alpha Psychiatry · 23.10.2026 · 27 (5)

DOI: 10.31083/ap53996 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Alpha Psychiatry, online erschienen am 23.10.2026. Verfasst von Álvaro Moleón-Ruiz und 9 weiteren Autor:innen. Beteiligte Einrichtung: Psychiatry Service, Hospital Virgen del Rocío, 41013 Seville, Spain. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Obsessive–compulsive symptoms frequently co-occur with depression and anxiety, contributing to a complex and potentially treatment-resistant clinical phenotype. Although transcranial magnetic stimulation (TMS) is an established treatment option for obsessive–compulsive disorder (OCD), many patients continue to experience residual symptoms across multiple domains. Multi-target neuromodulation approaches may help address overlapping neural circuits. This study evaluated the real-world effectiveness and feasibility of an accelerated Triple-Target Obsessive–Depressive–Anxious (aTTODA) theta-burst stimulation protocol.

Methods

In this naturalistic cohort study, 25 patients with treatment-resistant depressive–anxious disorder and comorbid OCD were treated with TMS at a specialized neuropsychiatric center. All patients received the accelerated aTTODA protocol, consisting of 30 sessions delivered over 3 weeks. Obsessive–compulsive, depressive, and anxiety symptoms were assessed at baseline and post-treatment using the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), 17-item Hamilton Depression Rating Scale (HDRS-17), and Hamilton Anxiety Rating Scale (HAM-A), respectively.

Results

Treatment with the aTTODA protocol was associated with significant improvements across all symptom domains (all p < 0.001), with large within-group effect sizes (Cohen’s d ≥1.0). Mean symptom reductions were 32.7% for the Y-BOCS, 44.6% for the HDRS-17, and 42.1% for the HAM-A. For OCD symptoms, 40% of patients met response criteria and 20% achieved remission. A shift toward lower Y-BOCS severity categories was also observed following treatment, suggesting broad clinical improvement beyond changes in mean symptom scores.

Conclusions

In this complex, treatment-resistant population, the accelerated multi-target aTTODA protocol was associated with clinically meaningful improvements across obsessive–compulsive, depressive, and anxiety symptom domains. These preliminary findings support the feasibility of time-efficient, circuit-based neuromodulation strategies. However, controlled randomized, blinded, sham-controlled trials are needed to establish efficacy, durability of treatment effects, and optimal patient selection.

Schlagwörter

Stichwörter der Autor:innen

OCDcomorbidityneuromodulationtheta-burst stimulationtranscranial magnetic stimulationtreatment-resistant depression

Autor:innen und Institutionen

  • Psychiatry Service, Hospital Virgen del Rocío, 41013 Seville, Spain.
  • Instituto Andaluz de Salud Cerebral, 41010 Seville, Spain.
  • Clinical Medicine Department, Universidad Miguel Hernández, 03202 Alicante, Spain.
  • Psychiatry Department, Hospital Universitario de San Juan, 03550 Alicante, Spain.
  • CIBERSAM-ISCIII (Biomedical Research Networking Centre for Mental Health), 28029 Madrid, Spain.
  • Department of Psychiatry and Neurosciences Research Group (CTS-549), Institute of Neurosciences, University of Granada, 18012 Granada, Spain.

ORCID-Profile: Álvaro Moleón-Ruiz, Lucía Duque-Fernández, Paloma Álvarez de Toledo, Lorena García-Fernández, Francisco Javier Narbona-Antunez, Luis Gutiérrez-Rojas, Roberto Rodriguez-Jimenez, Manuela Martín-Bejarano

Zitieren

APA

Moleón-Ruiz, Á., Duque-Fernández, L., Regidor, C., Álvarez de Toledo, P., Martín-García, G., García-Fernández, L., Narbona-Antunez, F. J., Gutiérrez-Rojas, L., Rodriguez-Jimenez, R., & Martín-Bejarano, M. (2026). Accelerated Multi-Target Theta-Burst Stimulation for Obsessive–Depressive–Anxious Symptoms: Real-World Outcomes of the aTTODA Protocol. Alpha Psychiatry, 27(5). https://doi.org/10.31083/ap53996

Vancouver

Moleón-Ruiz Á, Duque-Fernández L, Regidor C, Álvarez de Toledo P, Martín-García G, García-Fernández L, et al. Accelerated Multi-Target Theta-Burst Stimulation for Obsessive–Depressive–Anxious Symptoms: Real-World Outcomes of the aTTODA Protocol. Alpha Psychiatry. 2026;27(5). doi:10.31083/ap53996

BibTeX
@article{MolenRuiz2026,
  author = {Moleón-Ruiz, Álvaro and Duque-Fernández, Lucía and Regidor, Clara and Álvarez de Toledo, Paloma and Martín-García, Gonzalo and García-Fernández, Lorena and Narbona-Antunez, Francisco Javier and Gutiérrez-Rojas, Luis and Rodriguez-Jimenez, Roberto and Martín-Bejarano, Manuela},
  title = {Accelerated Multi-Target Theta-Burst Stimulation for Obsessive–Depressive–Anxious Symptoms: Real-World Outcomes of the aTTODA Protocol},
  journal = {Alpha Psychiatry},
  year = {2026},
  volume = {27},
  number = {5},
  doi = {10.31083/ap53996}
}
Kostenlos starten →